Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an intravenous formulation for hospital use. It is employed to reduce the risk of cerebral vasospasm following subarachnoid hemorrhage, helping to maintain adequate cerebral blood flow in affected patients.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global healthcare providers.

Nimodipine is a cerebral vasodilator used in the management of vascular complications after subarachnoid hemorrhage. By targeting delayed arterial narrowing, it helps to prevent secondary ischemic injury.

- Aneurysmal subarachnoid hemorrhage: prevention of cerebral vasospasm and associated delayed ischemia. - Post‑operative cerebral vasospasm: reduction of vasospastic episodes after neurosurgical interventions.

Nimodipine may be associated with several adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Flushing: warmth and redness of skin. - Nausea: occasional upset stomach. - Dizziness: sensation of light‑headedness. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure decline requiring intervention. - Myocardial infarction: rare cardiac ischemic event. - Arrhythmia: abnormal heart rhythm. - Hepatic dysfunction: elevated liver enzymes. - Allergic reaction: rash, pruritus, or anaphylaxis. - Neutropenia: reduced neutrophil count.

When using Nimodipine, clinicians should observe specific safety measures to minimize risk.

- Blood pressure monitoring: check systolic and diastolic values before and during infusion. - Cardiac function: assess for pre‑existing heart disease. - Renal impairment: adjust monitoring in patients with reduced clearance. - Concomitant vasodilators: avoid additive hypotensive effects. - Pregnancy and lactation: use only if benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Nimodipine can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Combined use with other calcium channel blockers: risk of profound hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma levels. - Nitrates: additive vasodilatory effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Beta‑blockers: monitor heart rate and blood pressure. - Diuretics: watch for volume depletion.